10-Year diabetes study tracks 1,000 patients after groundbreaking treatment
NCT ID NCT07360080
Summary
This study follows 1,000 people with early-stage Type 1 diabetes for up to 10 years after they receive teplizumab treatment in regular medical care. Researchers want to see how well the treatment delays the need for insulin and affects patients' quality of life over time. The study will track diabetes complications, blood sugar control, and how patients feel emotionally while living with the condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 3760001
RECRUITINGRamat Gan, 5265601, Israel
Conditions
Explore the condition pages connected to this study.